The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group

OBJECTIVE: The aim of this study was to prospectively investigate the efficacy and safety profiles of low-dose dasatinib therapy (50 mg once daily). METHODS: Patients with chronic myeloid leukemia in the chronic phase (CML-CP) who were being treated with low-dose imatinib (≤200 mg/day), but were res...

Descripción completa

Detalles Bibliográficos
Autores principales: Iriyama, Noriyoshi, Ohashi, Kazuteru, Hashino, Satoshi, Kimura, Shinya, Nakaseko, Chiaki, Takano, Hina, Hino, Masayuki, Uchiyama, Michihiro, Morita, Satoshi, Sakamoto, Junichi, Sakamaki, Hisashi, Inokuchi, Koiti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799051/
https://www.ncbi.nlm.nih.gov/pubmed/29033428
http://dx.doi.org/10.2169/internalmedicine.9035-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799051/
https://www.ncbi.nlm.nih.gov/pubmed/29033428
http://dx.doi.org/10.2169/internalmedicine.9035-17

Ejemplares similares